Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart: DPD2) has completed assembly of its i/Blue Imaging System’s functional unit, which has met the company’s pre-established performance expectations.
The functional unit, which is 70% smaller than its preceding proof-of-principle prototype, is operating as anticipated to provide simultaneous high-resolution images in both blue and white light modes.
With the first step of the functional system stage complete, Imagin will begin building additional units with enhanced software that will be verified for multiple functions, such as electrical safety, and reprocessing and sterilization. “We are currently conducting focus groups with urologists to optimize the software user interface and to meet precise functionality requirements,” Jim Hutchens, Imagin’s president and CEO, said in a statement.
Imagin Medical believes the i/Blue system could dramatically improve surgeons’ ability to visualize cancerous cells during minimally invasive surgeries. “We believe that the i/Blue technology’s many advantages, combined with product’s expected price point, have significant potential for bringing blue light cystoscopy into the mainstream standard of care for bladder cancer,” he added.
Imagin expects the functional system stage will be complete in mid-2019, positioning the company to initiate the next stages of product development: pilot production and product validation.
